141 related articles for article (PubMed ID: 33676174)
1. Identification of CXCL13/CXCR5 axis's crucial and complex effect in human lung adenocarcinoma.
Tian C; Li C; Zeng Y; Liang J; Yang Q; Gu F; Hu Y; Liu L
Int Immunopharmacol; 2021 May; 94():107416. PubMed ID: 33676174
[TBL] [Abstract][Full Text] [Related]
2. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma.
Park S; Cha H; Kim HS; Lee B; Kim S; Kim TM; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Cancer Med; 2023 Mar; 12(6):7639-7650. PubMed ID: 36453453
[TBL] [Abstract][Full Text] [Related]
4. CXC chemokine ligand-13 promotes metastasis via CXCR5-dependent signaling pathway in non-small cell lung cancer.
Chao CC; Lee WF; Wang SW; Chen PC; Yamamoto A; Chang TM; Weng SL; Liu JF
J Cell Mol Med; 2021 Oct; 25(19):9128-9140. PubMed ID: 34427969
[TBL] [Abstract][Full Text] [Related]
5. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.
Liao Y; He D; Wen F
Immunogenetics; 2021 Oct; 73(5):369-380. PubMed ID: 34302518
[TBL] [Abstract][Full Text] [Related]
6. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
[TBL] [Abstract][Full Text] [Related]
7. IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media.
Pimenta EM; De S; Weiss R; Feng D; Hall K; Kilic S; Bhanot G; Ganesan S; Ran S; Barnes BJ
Immunol Cell Biol; 2015; 93(5):486-99. PubMed ID: 25533286
[TBL] [Abstract][Full Text] [Related]
8. CXCL13 Signaling in the Tumor Microenvironment.
Hussain M; Liu J; Wang GZ; Zhou GB
Adv Exp Med Biol; 2021; 1302():71-90. PubMed ID: 34286442
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome Network Analysis Identifies CXCL13-CXCR5 Signaling Modules in the Prostate Tumor Immune Microenvironment.
Ohandjo AQ; Liu Z; Dammer EB; Dill CD; Griffen TL; Carey KM; Hinton DE; Meller R; Lillard JW
Sci Rep; 2019 Oct; 9(1):14963. PubMed ID: 31628349
[TBL] [Abstract][Full Text] [Related]
10. RelA driven co-expression of CXCL13 and CXCR5 is governed by a multifaceted transcriptional program regulating breast cancer progression.
Biswas S; Roy Chowdhury S; Mandal G; Purohit S; Gupta A; Bhattacharyya A
Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):502-511. PubMed ID: 30553016
[TBL] [Abstract][Full Text] [Related]
11. Immune profile of the tumor microenvironment and the identification of a four-gene signature for lung adenocarcinoma.
Fan T; Zhu M; Wang L; Liu Y; Tian H; Zheng Y; Tan F; Sun N; Li C; He J
Aging (Albany NY); 2020 Dec; 13(2):2397-2417. PubMed ID: 33318300
[TBL] [Abstract][Full Text] [Related]
12. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
[TBL] [Abstract][Full Text] [Related]
13. CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway.
Zhu Z; Zhang X; Guo H; Fu L; Pan G; Sun Y
Mol Cell Biochem; 2015 Feb; 400(1-2):287-95. PubMed ID: 25476740
[TBL] [Abstract][Full Text] [Related]
14. The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.
Zanetti C; Kumar R; Ender J; Godavarthy PS; Hartmann M; Hey J; Breuer K; Weissenberger ES; Minciacchi VR; Karantanou C; Gu Z; Roberts KG; Metzler M; Stock W; Mullighan CG; Bloomfield CD; Filmann N; Bankov K; Hartmann S; Hasserjian RP; Cousins AF; Halsey C; Plass C; Lipka DB; Krause DS
Blood; 2021 Nov; 138(19):1870-1884. PubMed ID: 34424946
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
16. PD-1
Li JP; Wu CY; Chen MY; Liu SX; Yan SM; Kang YF; Sun C; Grandis JR; Zeng MS; Zhong Q
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253636
[TBL] [Abstract][Full Text] [Related]
17. Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.
Hsieh CH; Jian CZ; Lin LI; Low GS; Ou PY; Hsu C; Ou DL
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053457
[TBL] [Abstract][Full Text] [Related]
18. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
[TBL] [Abstract][Full Text] [Related]
19. CXCL13/CXCR5 signaling axis in cancer.
Hussain M; Adah D; Tariq M; Lu Y; Zhang J; Liu J
Life Sci; 2019 Jun; 227():175-186. PubMed ID: 31026453
[TBL] [Abstract][Full Text] [Related]
20. CXCR5 is critically involved in progression of lupus through regulation of B cell and double-negative T cell trafficking.
Wiener A; Schippers A; Wagner N; Tacke F; Ostendorf T; Honke N; Tenbrock K; Ohl K
Clin Exp Immunol; 2016 Jul; 185(1):22-32. PubMed ID: 26990531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
